Innate Pharma SA (OTCMKTS:IPHYF) Sees Large Growth in Short Interest

Innate Pharma SA (OTCMKTS:IPHYF) saw a significant growth in short interest in May. As of May 15th, there was short interest totaling 23,016 shares, a growth of ? from the April 30th total of 0 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 36 shares, the short-interest ratio is currently 639.3 days.

Innate Pharma Price Performance

Shares of OTCMKTS IPHYF remained flat at $1.65 during mid-day trading on Monday. The stock’s 50 day simple moving average is $1.63 and its 200 day simple moving average is $1.94. Innate Pharma has a fifty-two week low of $1.37 and a fifty-two week high of $2.25.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.